<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alendronate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alendronate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Alendronate: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9427" href="/d/html/9427.html" rel="external">see "Alendronate: Drug information"</a> and <a class="drug drug_patient" data-topicid="12489" href="/d/html/12489.html" rel="external">see "Alendronate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F131404"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Binosto;</li>
<li>Fosamax</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865591"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Alendronate;</li>
<li>AG-Alendronate;</li>
<li>Alendronate-70;</li>
<li>APO-Alendronate;</li>
<li>Auro-Alendronate;</li>
<li>DOM-Alendronate [DSC];</li>
<li>DOM-Alendronate-FC;</li>
<li>Fosamax;</li>
<li>GEN-Alendronate;</li>
<li>JAMP-Alendronate;</li>
<li>JAMP-Alendronate Sodium;</li>
<li>M-Alendronate;</li>
<li>MINT-Alendronate;</li>
<li>NRA-Alendronate;</li>
<li>PMS-Alendronate-FC;</li>
<li>RIVA-Alendronate;</li>
<li>SANDOZ Alendronate;</li>
<li>TEVA-Alendronate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F996597"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Bisphosphonate Derivative</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812477"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="623ef40c-b465-4034-b9a8-fb2518234261">Osteogenesis imperfecta</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteogenesis imperfecta:</b>
<b>Note:</b> Intravenous bisphosphonates may be preferred over oral options due to improved outcomes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28863000','lexi-content-ref-31693577','lexi-content-ref-29504223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28863000','lexi-content-ref-31693577','lexi-content-ref-29504223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Daily dosing: </i>Limited data available, dosing regimens and efficacy results variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18310788','lexi-content-ref-15832149','lexi-content-ref-16294137','lexi-content-ref-21106710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18310788','lexi-content-ref-15832149','lexi-content-ref-16294137','lexi-content-ref-21106710'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">≤30 kg: Oral: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">30 to &lt;40 kg: 5 or 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥40 kg: Oral: 10 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a5298e2-1f8e-4225-8e59-e5e6fc704ab1">Osteopenia/Osteoporosis, patients with acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteopenia</b>
<b>/Osteoporosis, patients with acute lymphoblastic leukemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weekly dosing: </i>Limited data available: (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17805035','lexi-content-ref-36729669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17805035','lexi-content-ref-36729669'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">15 to &lt;25 kg: Oral: 20 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">25 to &lt;35 kg: Oral: 30 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">35 to &lt;45 kg: Oral: 40 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">45 to &lt;55 kg: Oral: 50 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">55 to &lt;65 kg: Oral: 60 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">≥65 kg: Oral: 70 mg once <b>weekly</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8a2408aa-fe45-4635-943a-7c363770df8d">Osteopenia/Osteoporosis, patients with chronic diseases</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteopenia/Osteoporosis</b>
<b>, patients with chronic diseases</b> (eg, connective tissue disorders, cystic fibrosis, rheumatologic disorders): Limited data available, optimal regimen not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Daily dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11014345','lexi-content-ref-24429202','lexi-content-ref-12180745','lexi-content-ref-16759038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11014345','lexi-content-ref-24429202','lexi-content-ref-12180745','lexi-content-ref-16759038'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">&lt;20 kg: Oral: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">20 to &lt;30 kg: Oral: 5 or 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥30 kg: Oral: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weekly dosing</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17912140','lexi-content-ref-23835890','lexi-content-ref-31573608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17912140','lexi-content-ref-23835890','lexi-content-ref-31573608'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥11 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">≤30 kg: Oral: 35 mg once <b>weekly</b>.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;30 kg: Oral: 70 mg once <b>weekly</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F53308052"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, use is not recommended in patients with a CrCl of &lt;35 mL/minute.</p></div>
<div class="block dohp drugH1Div" id="F53308053"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations provided in the manufacturer's labeling; based on experience in adult patients, no adjustment required.</p></div>
<div class="block doa drugH1Div" id="F131408"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9427" href="/d/html/9427.html" rel="external">see "Alendronate: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="42d9f687-8a9c-4d6e-86a3-00829eb78170">Osteoporosis, fracture risk reduction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis, fracture risk reduction</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Correct hypocalcemia and vitamin D deficiency (eg, to a 25-hydroxyvitamin D level ≥20 ng/mL [≥50 nmol/L]) prior to initiating therapy and ensure adequate calcium and vitamin D intake during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-34448749','lexi-content-ref-Rosen.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Males and postmenopausal females:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients with high fracture risk, including those with a history of fragility fracture, </i>
<b>
<i>or</i></b>
<i> males ≥50 years of age and postmenopausal females with a T-score of −2.5 or lower or a T-score between −1 and −2.5 at high fracture risk according to a risk assessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Finkelstein.1','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Finkelstein.1','lexi-content-ref-25182228'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Treatment: Oral:</b> 70 mg once weekly <b>or </b>10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Patients without high fracture risk, including those with a T-score between −1 and −2.5 and who are </i>
<b>
<i>not </i></b>
<i>at high fracture risk according to a risk assessment, but who desire pharmacologic therapy for prevention of bone loss or fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lewiecki.1','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lewiecki.1','lexi-content-ref-25182228'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Prevention:</b>
<b>Oral:</b> 35 mg once weekly <b>or </b>5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Duration of therapy:</b> The optimal duration of therapy has not been established. Consider discontinuing after 5 years if bone mineral density (BMD) is stable, there have been no previous fragility fractures, and short-term fracture risk is low. If fracture risk remains high (eg, fragility fracture before or during therapy), consider extending therapy for up to 10 years or switching to alternative therapy. If discontinued, the decision to resume therapy is based on multiple factors, including decline in BMD and risk factors for fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953','lexi-content-ref-20173017'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Glucocorticoid-induced: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in males ≥50 years of age and postmenopausal females with low BMD (T-scores between −1 and −2.5 in either group) and expected to receive systemic glucocorticoid therapy for at least 3 months at a prednisone dose of ≥7.5 mg/day (or its equivalent) <b>or</b> in any patient whose baseline risk of fracture is high and is receiving a glucocorticoid at any dose or duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>). In younger males and premenopausal females, patient selection must be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Rosen.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Rosen.2'])">Ref</a></span>). Avoid use in females who are pregnant, who plan on becoming pregnant, or who are not using effective birth control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Prevention (off-label use) or treatment: Oral:</b> 70 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19487264','lexi-content-ref-19004038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19487264','lexi-content-ref-19004038'])">Ref</a></span>) <b>or </b>10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16914703','lexi-content-ref-22105813']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16914703','lexi-content-ref-22105813'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy: The optimal duration of treatment has not been established; duration should be individualized based on continuation of glucocorticoid therapy and fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28585373','lexi-content-ref-35378630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28585373','lexi-content-ref-35378630'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="659fa148-593d-411f-81cc-a07b63850a4e">Paget disease, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Paget disease, treatment (alternative agent): Note: </b>For symptomatic patients with active disease and select patients with asymptomatic disease (eg, abnormal biochemical marker, prior to planned surgery at an active pagetic site) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Charles.1','lexi-content-ref-25406796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Charles.1','lexi-content-ref-25406796'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial: <b>Oral:</b> 40 mg once daily for 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25406796','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25406796','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Re-treatment: A second course (ie, 40 mg orally once daily for 6 months) may be considered following a 6-month posttreatment evaluation period in patients whose serum alkaline phosphatase normalized during initial treatment but then subsequently rose above normal after discontinuation <b>or</b> if serum alkaline phosphatase failed to normalize during the initial course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Charles.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Charles.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bddc9a03-d14e-4739-9e13-19dee5b34eb0">Prostate cancer, bone loss associated with androgen deprivation therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prostate cancer, bone loss associated with androgen deprivation therapy (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in males <b>without</b> bone metastases treated long term with androgen deprivation therapy who are at elevated risk of osteoporotic fractures (eg, T-score of –2.5 or lower, prior fragility fracture, or T-score between –1 and –2.5 at high fracture risk according to a risk assessment tool) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31990618','lexi-content-ref-31532726']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31990618','lexi-content-ref-31532726'])">Ref</a></span>). Due to uncertain efficacy relative to preferred agents, some experts recommend against the use of alendronate for this indication unless preferred agents are unavailable or inappropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Smith.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Smith.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 70 mg once weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17097529','lexi-content-ref-17371886','lexi-content-ref-23040208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17097529','lexi-content-ref-17371886','lexi-content-ref-23040208'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Missed doses (once weekly):</b></i> If a once-weekly dose is missed, administer the next morning after remembered; then return to the original scheduled day of the week on the once-weekly schedule; however, do not administer 2 doses on the same day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990653"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥35 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;35 mL/minute: Use not recommended (manufacturer’s labeling). However, based on limited data, use of an unadjusted dose may be considered in patients with CrCl of &gt;25 to &lt;35 mL/minute and without underlying CKD-mineral and bone disorder when the benefits outweigh the risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20347511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20347511'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bailie.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bailie.1'])">Ref</a></span>): Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis: </b>Use not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987867"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block arsc drugH1Div" id="F55038168"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Atypical femur fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Atypical <b>femur fractures</b> (AFF) have been reported with bisphosphonate use, including alendronate. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). The benefits of therapy (when used for osteoporosis) generally outweigh the absolute risk of AFF within the first 5 years of treatment, especially in patients with high fracture risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-30907953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-30907953'])">Ref</a></span>). The risk decreases after bisphosphonate discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32813950'])">Ref</a></span>). AFF is estimated to occur in ~0.2 % of bisphosphonate users after ≥5 years of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21343577'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related. Long-term suppression of bone turnover may be primarily responsible; however, microdamage accumulation and alterations of collagen cross-linking have also been postulated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31497503','lexi-content-ref-23712442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31497503','lexi-content-ref-23712442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; most fractures have occurred in patients receiving alendronate for at least 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21343577']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21343577'])">Ref</a></span>). Patients may experience prodromal pain weeks or months before the fracture occurs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20842676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20842676'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term treatment (&gt;3 to 5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26350171','lexi-content-ref-FDA.2018','lexi-content-ref-25182228']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26350171','lexi-content-ref-FDA.2018','lexi-content-ref-25182228'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Asian race (in North America) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Femoral bowing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Glucocorticoid use (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30169557','lexi-content-ref-32813950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30169557','lexi-content-ref-32813950'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI mucosal irritation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophagitis</b>,<b> dysphagia</b>, <b>esophageal ulcer</b>, <b>erosive esophagitis</b>, <b>esophageal stenosis </b>(rare), and <b>esophageal perforation</b> (rare) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21736407','lexi-content-ref-22778283','lexi-content-ref-21343270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21736407','lexi-content-ref-22778283','lexi-content-ref-21343270'])">Ref</a></span>) have been reported. <b>Oropharyngeal ulcer</b> has also been noted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20674418','lexi-content-ref-21816532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20674418','lexi-content-ref-21816532'])">Ref</a></span>). Experiencing a GI event increases the likelihood of decreased compliance at 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27112533']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27112533'])">Ref</a></span>) or discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16678644','lexi-content-ref-12947959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16678644','lexi-content-ref-12947959'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> GI mucosal irritation is secondary to the local effect of alendronate on the gastric mucosa (as opposed to a systemic effect) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; dependent upon the type of mucosal injury, but case reports have noted onset within 2 days to 12 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21736407','lexi-content-ref-21816532','lexi-content-ref-22778283','lexi-content-ref-21343270']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21736407','lexi-content-ref-21816532','lexi-content-ref-22778283','lexi-content-ref-21343270'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Incorrect administration technique (ie, &lt;180 mL water, lying down after administration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent nonsteroidal anti-inflammatory drug or antithrombotic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-30626809']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-30626809'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior GI issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25866298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25866298'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypocalcemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">While transient <b>decreased serum calcium</b> is expected with the use of alendronate (and all bisphosphonates) secondary to their mechanism of action, cases of symptomatic <b>hypocalcemia</b> have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10878202','lexi-content-ref-16524863','lexi-content-ref-10068397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10878202','lexi-content-ref-16524863','lexi-content-ref-10068397'])">Ref</a></span>). This has been seen in the setting of a known or unknown diagnosis of hypoparathyroidism and is reversible with discontinuation of alendronate, regardless of cause.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> By decreasing osteoclast activity, calcium is not released into the bloodstream, causing a transient decrease in blood calcium. In patients with normally functioning parathyroid glands, calcium homeostasis is regained shortly after starting the bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8298198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8298198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; case reports have noted onset of symptomatic hypocalcemia within 10 days to 12 weeks of initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10878202','lexi-content-ref-16524863','lexi-content-ref-10068397']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10878202','lexi-content-ref-16524863','lexi-content-ref-10068397'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline hypocalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Impaired parathyroid function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Vitamin D deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Osteonecrosis of the jaw</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteonecrosis of the jaw</b> (ONJ) was first described in dental literature (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12966493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12966493'])">Ref</a></span>) with the use of IV bisphosphonates. However, there is conflicting evidence of whether this risk is seen with oral bisphosphonates, such as alendronate, or is simply an increased risk in those who are treated with agents for osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24758181','lexi-content-ref-24515577','lexi-content-ref-21764202']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24758181','lexi-content-ref-24515577','lexi-content-ref-21764202'])">Ref</a></span>). ONJ is most commonly reversible and not life-threatening; however, the possibility of ONJ increases the risk of nonadherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28602783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28602783'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; exact mechanism unknown, but several hypothesized mechanisms exist, such as oversuppression of bone turnover (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16243172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16243172'])">Ref</a></span>), mucosal toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16454811']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16454811'])">Ref</a></span>), cytokine-mediated inflammation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17614762']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17614762'])">Ref</a></span>), and infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19371816','lexi-content-ref-25710950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19371816','lexi-content-ref-25710950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; can be spontaneous or after insult, such as tooth extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-30393090'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol use disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Anemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cancer and anticancer therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Corticosteroid therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dental extraction and/or dental implant procedures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21504254','lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21504254','lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extended duration (&gt;3 years) of bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High-dose, IV bisphosphonate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Immunological disorders (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Oral surgery or trauma (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poor oral hygiene (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Poorly fitting dental appliance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Radiotherapy to head and neck (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30393090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30393090'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tobacco smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17663640']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17663640'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F131373"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences of adverse reactions (mostly GI) increase significantly in patients treated for Paget disease at 40 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Decreased serum calcium (18%; transient, mild)<span class="lexi-table-link-container"> (<a aria-label="Alendronate: Adverse Reaction: Decreased Serum Calcium table link" class="lexi-table-link" data-table-id="lexi-content-alendronate-adverse-reaction-decreased-serum-calcium" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-alendronate-adverse-reaction-decreased-serum-calcium')">table 1</a>)</span><span class="table-link" style="display:none;">Alendronate: Adverse Reaction: Decreased Serum Calcium</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Alendronate: Adverse Reaction: Decreased Serum Calcium" frame="border" id="lexi-content-alendronate-adverse-reaction-decreased-serum-calcium" rules="all">
<caption style="text-align:center;">
<b>Alendronate: Adverse Reaction: Decreased Serum Calcium</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alendronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication </b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum phosphate (10%; transient, mild)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension (≤1%), abdominal pain (2% to 7%), acid regurgitation (1% to 5%), constipation (≤3%), diarrhea (≤3%), dyspepsia (1% to 3%), dysphagia (≤1%)<span class="lexi-table-link-container"> (<a aria-label="Alendronate: Adverse Reaction: Dysphagia table link" class="lexi-table-link" data-table-id="lexi-content-alendronate-adverse-reaction-dysphagia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-alendronate-adverse-reaction-dysphagia')">table 2</a>)</span><span class="table-link" style="display:none;">Alendronate: Adverse Reaction: Dysphagia</span>, esophageal ulcer (≤2%)<span class="lexi-table-link-container"> (<a aria-label="Alendronate: Adverse Reaction: Esophageal Ulcer table link" class="lexi-table-link" data-table-id="lexi-content-alendronate-adverse-reaction-esophageal-ulcer" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-alendronate-adverse-reaction-esophageal-ulcer')">table 3</a>)</span><span class="table-link" style="display:none;">Alendronate: Adverse Reaction: Esophageal Ulcer</span>, flatulence (≤4%), gastric ulcer (≤1%; may be severe with complications), gastritis (≤1%), gastroesophageal reflux disease (3%), melena (1%), nausea (1% to 3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Alendronate: Adverse Reaction: Dysphagia" frame="border" id="lexi-content-alendronate-adverse-reaction-dysphagia" rules="all">
<caption style="text-align:center;">
<b>Alendronate: Adverse Reaction: Dysphagia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alendronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alendronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">196</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">397</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,236</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,223</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Alendronate: Adverse Reaction: Esophageal Ulcer" frame="border" id="lexi-content-alendronate-adverse-reaction-esophageal-ulcer" rules="all">
<caption style="text-align:center;">
<b>Alendronate: Adverse Reaction: Esophageal Ulcer</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Alendronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Alendronate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">196</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">397</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Osteoporosis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,236</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3,223</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps (≤1%), musculoskeletal pain (≤6%; includes bone pain, joint pain, and muscle pain)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Gastrointestinal: Dysgeusia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, erythema of skin, skin rash (occasionally with photosensitivity), Stevens-Johnson syndrome, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia (symptomatic) (Maalouf 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Duodenal ulcer (may be severe with complications), erosive esophagitis (de Groen 1996), esophageal perforation (Munigoti 2010), esophageal stenosis (Aibar Arregui 2011), esophagitis (de Groen 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (includes angioedema and urticaria) (Kontoleon 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, malaise, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia, femur fracture (low-energy fractures, including atypical subtrochanteric and diaphyseal) (Park-Wyllie 2011), joint swelling, osteonecrosis (cholesteatoma of the external auditory canal), osteonecrosis of the jaw (rare: &lt;1%) (Lewiecki 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Episcleritis, scleritis (Leung 2005), uveitis (Malik 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of asthma, oropharyngeal ulcer (Kharazmi 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F131388"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to alendronate or any component of the formulation; hypocalcemia; abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying; inability to stand or sit upright for at least 30 minutes; increased risk of aspiration (effervescent tablets; oral solution)</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Renal insufficiency with CrCl &lt;35 mL/minute</p></div>
<div class="block war drugH1Div" id="F131370"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone/joint/muscle pain: Severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with the same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery: Altered absorption and ulceration risk: Avoid oral bisphosphates after bariatric surgery; inadequate oral absorption and potential anastomotic ulceration may occur. If therapy is indicated, IV administered bisphosphonates are recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Effervescent tablet: Each effervescent tablet contains 603 mg of sodium (NaCl 1,532 mg). Use with caution in patients following a sodium-restricted diet. <b>Note:</b> Prior to October 2020, the sodium content was listed as 650 mg/tablet (NaCl 1,650 mg/tablet) in the manufacturer’s labeling.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878318"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Possible decreased bone remodeling affecting growth or fracture healing may occur with bisphosphonate therapy; a case report in an adolescent treated with high-dose pamidronate described abnormal long-bone modeling (Rauch 2004); a large, placebo-controlled osteogenesis imperfecta trial (n=109, age range: 4 to 19 years) reported that alendronate did not interfere with fracture healing (Ward 2011).</p></div>
<div class="block prod-avail drugH1Div" id="F55424552"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Alendronate 40 mg tablets have been discontinued in the US for more than 1 year.</p></div>
<div class="block foc drugH1Div" id="F131381"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 70 mg/75 mL (75 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosamax: 70 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 35 mg, 70 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Effervescent, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Binosto: 70 mg</p></div>
<div class="block geq drugH1Div" id="F131366"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F131390"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Alendronate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg/75 mL (per mL): $1.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, effervescent</b> (Binosto Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $90.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Alendronate Sodium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $0.69 - $52.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $0.80 - $59.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Fosamax Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70 mg (per each): $44.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865592"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosamax: 70 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 40 mg, 70 mg</p></div>
<div class="block admp drugH1Div" id="F52612195"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer first thing in the morning and ≥30 minutes before the first food, beverage (except plain water), or other medication of the day. Do not take with mineral water or with other beverages. Remain upright (do not lie down) for at least 30 minutes <b>and</b> until after first food of the day (to reduce esophageal irritation).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Follow administration of oral solution with at least 2 oz of plain water.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet (Fosamax): Must be taken with 6 to 8 oz of plain water. The tablet should be swallowed whole; do not chew or suck on the tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, effervescent (Binosto): Dissolve one tablet in 4 oz (120 mL) of room temperature plain water only; once effervescence stops, wait ≥5 minutes and stir the solution for ~10 seconds and then drink.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses: Once weekly dosing:</i> If a once-weekly dose is missed, it should be given the next morning after remembered; then return to the original scheduled day of the week on the once-weekly schedule; however, do not give 2 doses on the same day.</p></div>
<div class="block adm drugH1Div" id="F131385"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer first thing in the morning and ≥30 minutes before the first food, beverage (except plain water), or other medication(s) of the day. Do not take with mineral water or with other beverages. Patients should be instructed to stay upright (not to lie down) for ≥30 minutes <b>and</b> until after first food of the day (to reduce esophageal irritation).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Administer oral solution, followed with ≥2 oz of plain water.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet (Fosamax): Must be taken with 6 to 8 oz of plain water. The tablet should be swallowed whole; do not chew or suck.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, effervescent (Binosto): Do not swallow, chew, or allow undissolved tablet to dissolve in mouth. Dissolve one tablet in 4 oz of room temperature plain water only; once effervescence stops, wait ≥5 minutes and stir the solution for ~10 seconds and then drink.</p></div>
<div class="block sts drugH1Div" id="F131399"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Oral solution: Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet (Fosamax): Store at room temperature of 15°C to 30°C (59°F to 86°F). Keep in well-closed container.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, effervescent (Binosto): Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture. Store in original blister package until use. </p></div>
<div class="block meg drugH1Div" id="F11441253"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Binosto: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2FBinostoMedGuide.pdf&amp;token=BwFgtfFNhNME4zAzBbnzl%2B7C5gWV8wdaiTC%2BsVI4CEOfAjMUmYDno8aDHHrTKAi2KLyuEabP3Xu5%2FA1L9Nt%2FEcaTJTz0cy5yQ9iiOa1NevqvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=114896" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/BinostoMedGuide.pdf</a></p>
<p style="text-indent:-2em;margin-left:4em;">Fosamax: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F020560s068%2C021575s024lbl.pdf%23page%3D24&amp;token=%2FTKh23YZ4GTZCjfAhuWJbLeAfwtEjSrhzGdvZJB%2Be85Dl2pDXmEiUIDIYLalMHCA6Bv7pg2XvIkS2qV%2FykwVbN51W5Bo9sgyhNrb9opwY8R4CbS0g3Es9iMNpuFgpJzE&amp;TOPIC_ID=114896" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020560s068,021575s024lbl.pdf#page=24</a></p></div>
<div class="block usep drugH1Div" id="F53565247"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of osteoporosis (Binosto, Fosamax: FDA approved in postmenopausal females and adult males); prevention of osteoporosis (Fosamax: FDA approved in postmenopausal females); treatment of Paget disease of the bone in patients who are symptomatic, at risk for future complications, or with alkaline phosphatase ≥2 times the upper limit of normal (Fosamax: FDA approved in adults); treatment of glucocorticoid-induced osteoporosis in patients with low bone mineral density who are receiving a daily dosage ≥7.5 mg of prednisone (or equivalent) (Fosamax: FDA approved in adults); has also been used in the treatment of osteogenesis imperfecta and osteopenia in cystic fibrosis, nonambulatory (eg, cerebral palsy), and rheumatology patients.</p></div>
<div class="block mst drugH1Div" id="F131431"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Alendronate may be confused with risedronate</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fosamax may be confused with Flomax, Fosamax Plus D, fosinopril, Zithromax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Fosamax  [US, Canada, and multiple international markets] may be confused with Fisamox brand name for amoxicillin [Australia]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298701"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F131375"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives. Aminoglycosides may enhance the nephrotoxic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: May enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parathyroid Hormone: Alendronate may diminish the therapeutic effect of Parathyroid Hormone. More specifically, Alendronate may interfere with normalization of blood calcium concentrations. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyvalent Cation Containing Products: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F131400"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">All food and beverages interfere with absorption. Coadministration with dairy products may decrease alendronate absorption. Beverages (especially orange juice, coffee, and mineral water) and food may reduce the absorption of alendronate as much as 60%. Management: Alendronate must be taken first thing in the morning and ≥30 minutes before the first food, beverage (except plain water), or other medication of the day.</p></div>
<div class="block dic drugH1Div" id="F131392"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Patients should consume:</p>
<p style="text-indent:-2em;margin-left:2em;">Calcium: 1,000 mg/day (males: 50 to 70 years of age) <b>or</b> 1,200 mg/day (females ≥51 years of age and males ≥71 years of age) (IOM 2011; NOF [Cosman 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D: 800 to 1,000 units/day (age ≥50 years) (NOF [Cosman 2014]). Recommended dietary allowance (RDA): 600 units daily (age ≤70 years) <b>or</b> 800 units/day (age ≥71 years) (IOM 2011).</p></div>
<div class="block rep_considerations drugH1Div" id="F49088794"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Underlying causes of osteoporosis should be evaluated and treated prior to considering bisphosphonate therapy in premenopausal women; effective contraception is recommended when bisphosphonate therapy is required (Pepe 2020). Bisphosphonates are incorporated into the bone matrix and gradually released over time. Because exposure prior to pregnancy may theoretically increase the risk of fetal harm, most sources recommend discontinuing bisphosphonate therapy in females of reproductive potential as early as possible prior to a planned pregnancy. Use in premenopausal females should be reserved for special circumstances when rapid bone loss is occurring; a bisphosphonate with the shortest half-life should then be used (Bhalla 2010; Pereira 2012; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Oral bisphosphonates can be considered for the prevention of glucocorticoid-induced osteoporosis in premenopausal females with moderate to high risk of fracture who do not plan to become pregnant during the treatment period and who are using effective birth control (or are not sexually active); intravenous therapy should be reserved for high risk patients only (Buckley [ACR 2017]).</p></div>
<div class="block pri drugH1Div" id="F131391"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">It is not known if bisphosphonates cross the placenta, but based on their lower molecular weight, fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to the use of alendronate in pregnancy is available from case reports and small retrospective studies (Gerin 2016; Green 2014; Levy 2009; Ornoy 2006; Sokal 2019; Stathopoulos 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by drug, dose, and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy (hypocalcemia, low birth weight, and decreased gestation have been observed in some case reports); however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Green 2014; Levy 2009; Machairiotis 2019; Sokal 2019; Stathopoulos 2011). Exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>
<div class="block mopp drugH1Div" id="F53565246"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Osteogenesis imperfecta: Serum calcium and phosphorus, alkaline phosphatase, urinary calcium/creatinine ratio every 3 months; bone mineral density (DEXA) at baseline and periodically with therapy (eg, every 6 to 12 months); annual skeletal survey (Akcay 2008; Seikaly 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">Osteopenia/Osteoporosis: Bone mineral density (baseline and periodically with therapy), number and location of fractures, height and weight, pain; serum calcium and 25(OH)D; alkaline phosphatase, biochemical markers of bone turnover.</p></div>
<div class="block pha drugH1Div" id="F131369"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.</p></div>
<div class="block phk drugH1Div" id="F131387"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 28 L (exclusive of bone)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~78%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: None</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Fasting:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥4 years and Adolescents: Mean range: 0.41% to 0.56% (Nakhla 2011; Ward 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 0.6%; reduced up to 60% with coffee or orange juice</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Exceeds 10 years</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine; feces (as unabsorbed drug)</p></div>
<div class="block phksp drugH1Div" id="F51219927"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Elimination may be reduced.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F131393"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fosamax | Fozanate | Lendomax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Actimax | Alenato | Alendronato Austral | Alendronato denver farma | Alendronato Lepetit | Alendronato northia | Apo alendronate | Arendal | Berlex | Brek | Elandur | Findeclin | Fosamax | Lendronal | Marvil | Oseotenk | Osteofene | Osteonate | Pamoseo | Phostarac | Regenesis | Reyoin | Rixofem | Silidral | Tilios</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Alendris | Alendrohexal | Alendromax | Alendron | Alendronat-Nycomed | Alendronsaeure 1A Pharma | Alendronsaeure Actavis | Alendronsaeure Arcana | Alendronsaeure bluefish | Alendronsaeure Pfizer | Alendronsaeure ratiopharm | Alendronsaeure sandoz | Alendronstad | Fosamax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Alendro | Alendrobell | Alendronate an | Alendronate pfizer | Alendronate sandoz | Alendronate-GA | Apo alendronate | Chemmart alendronate | Cm Alendronate | Densate | Fonat | Fosamax | Genrx Alendronate | Ossmax | Terry white chemists alendronate | Tw Alendronate</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Alendon | Ostel</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Alendromed | Alendronate Accord | Alendronate EG | Alendronate Merck | Alendronate Mylan | Alendronate pfizer | Alendronate Ratiopharm | Alendronate sandoz | Alendronate teva | Alendroninezuur Apotex | Fosamax</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Alendro | Bifosa | Ralenost</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Alendronat Actavis | Alendronic acid | Forosa | Fosamax | Fosamax ow | Fosanate | Lindron | Tevanate</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alendil | Alendosseo | Alendrin | Alendronato de sodio | Alendronato sodico | Alendrus | Bonagran | Bonalen | Boneprev | Cleveron | Endronax | Endrostan | Endrox | Fosamax | Ledar | Minusorb | Ossomax | Ostelox | Ostenan | Osteofar | Osteoform | Osteoral | Ostrat | Ostrazil | Recalfe | Terost</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Alendron Mepha | Alendronat Actavis | Alendronat Adico | Alendronat Helvepharm | Alendronat sandoz | Alendronat Spirig | Alendronat Streuli | Alendronat Teva | Alendronat zentiva | Binosto | Fosamax</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Alendro | Bifosa | Osteonate</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aldrox | Arendal | Fosamax | Fosval | Holadren | Leodrin | Oseotal | Oseum | Osteosan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">An lun | Fosamax | Gu bang | Tian ke</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alendrobal | Alendronato | Alendronato mk | Arendal | Armol | Bifemelan | Eucalen | Fixopan | Fosamax | Indrol | Labinfost | Lokar | Neobon | Osdronat | Osficar | Osfidronat | Ostertrin | Ostex | Osticalcin | Secnitron | Tibolene</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Alendronat Actavis | Alendronat Pliva | Alendronat sandoz | Alendronic acid aurobindo | Apo alendronat | Fosamax | Fosteofos | Gendron | Lindron | Siranin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Alendro Ksk | Alendro-Q | Alendromed | Alendron | Alendron einmal woechentlich | Alendron Hexal | Alendron Sandoz | Alendronat Acis | Alendronate pfizer | Alendronsaeure 1A Pharma | Alendronsaeure AbZ | Alendronsaeure Actavis | Alendronsaeure AL | Alendronsaeure AWD | Alendronsaeure Axcount | Alendronsaeure Basics | Alendronsaeure bioeq pharma | Alendronsaeure bluefish | Alendronsaeure CT | Alendronsaeure dura | Alendronsaeure Heumann | Alendronsaeure ratiopharm | Alendronsaeure stada | Alendronsaeure tecnimede | Alendronsaeure Volkspharma | Binosto | Fosamax | Tevanate</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Alendronat Ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alendronato | Alendronato Exels | Alendronato genfar | Arendal | Armol | Defixal | Dronat | Fixopan | Fosamax | Foseron | Fosfalen | Fosfoplus | Nor Ospor | Oseomax | Ossifix | Osteofel | Osteomax | Osteonato | Osteoplus | Porosin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aldrox | Alebay | Alendral | Alendronato | Alendronato mk | Alendronato sodico | Armol | Eucalen | Fixopan | Fosamax | Fosmin | Fosval | Ostat | Osteomix | Oxtalen | Porosin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Alendronic acid stada | Alenotop | Fosamax | Lendrate | Sedron</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alendene | Alendex | Alendomax | Bonalene | Bonapex | Borgalendro | Fosamax | Nofract | Osteomax | Osteomepha | Osteonate</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico | Acido alendronico Apotex | Acido alendronico ciclum | Acido alendronico mabo | Acido Alendronico pensa | Acido Alendronico Semanal | Acido alendronico semanal Aurobindo | Acido alendronico semanal Cuve | Acido alendronico semanal Davur | Acido alendronico semanal Normon | Acido alendronico semanal Pharmagenus | Acido alendronico semanal Qualigen | Acido alendronico semanal Ranbaxy | Acido alendronico semanal Rimafar | Acido alendronico semanal Tecnimede | Acido alendronico semanal Vir | Acido alendronico Stada | Adelan semanal | Alenvir Semanal | Bifoal semanal | Binosto | Calbion semanal | Fosamax | Lefosan semanal | Semandrol semanal | Soludronate semanal</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Lendomax | Sodium alendronate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Alendronat Actavis | Alendronat Arrow | Alendronat Bluefish | Alendronat mylan | Alendronat Orifarm | Alendronat Pfizer | Alendronat Ranbaxy | Alendronat Ratiopharm | Alendronat sandoz | Binosto | Bonasol | Fosamax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Acide alendronique | Acide Alendronique Almus | Acide Alendronique Alter | Acide Alendronique Arrow | Acide Alendronique Biogaran | Acide Alendronique EG | Acide alendronique evolugen | Acide Alendronique Merck | Acide alendronique phr lab | Acide Alendronique Qualimed | Acide alendronique Ranbaxy | Acide Alendronique Ratiopharm | Acide Alendronique Sandoz | Acide Alendronique Teva | Acide alendronique winthrop | Acide Alendronique Zydus | Bonasol | Fosamax | Steovess</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Alendronic | Alendronic acid | Alendronic Almus | Binosto | Fosamax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aledrolet | Alendral | Alendronate/mylan | Arthroplus | Aurodren | Binosto | Bone-aid | Debenal | Delfoza | Deparex | Dronalent | En Por | Enimon | Farmemax | Forosa | Fosalen | Fosamax | Fosandron | Fosazom | Ledronin | Linadax | Lozostun | Meldoz | Moralen | Mosmass | Osaston | Ostalert | Ostaven | Porocalm | Ridon | Zakodronate | Zemaros | Zulgar</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico | Alendon | Alendronate | Alendronate sandoz | Alovell | Apo alendronate | Bifosa | Euromax | Fosamax | Mosmass | Osteofos | Reventa | Samix</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aledox | Alendor | Forosa | Fosamax | Fosamax T | Valora</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Epolar | Fosamax | Massidron | Sedron | Trabecan teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Alenoxal | Alovell | Fosamax | Nichospor | Oslene | Osteofar | Voroste</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Alendronic acid | Alendronic acid bluefish once weekly | Binosto | Bonasol | Fosamax | Fostepor | Fostolin | Osteomel | Romax | Tevanate</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Alendronate teva | Fosalan | Maxibone</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Aldren | Alenost | Bifosa | Denfos | Dronal | Ostalen | Osteofos | Ostonat | Ralenost | Restofos | Zophost</span>;</li>
<li>
<span class="countryCode">(IR)</span> <span class="country">Iran, Islamic Republic of</span><span class="countrySeparator">: </span><span class="drugName">Osteofose</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico aurobindo | Acido alendronico tecnigen | Acido alendronico zentiva | Adronat | Alendronato | Alendronato Aahcl | Alendronato Actavis | Alendronato almus | Alendronato Bentley | Alendronato Doc | Alendronato EG | Alendronato Pensa | Alendronato Sandoz | Alendros | Aston | Binosto | Bonasol | Dralenos | Dronal | Fosamax | Genalen | Glamor | Loss | Porodron | Realen</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Alendronate sandoz | Alfa Porosis | Bonmax | Calidron | Dargol | Drolate | Fosamax | Foznate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alendronate | Alendronate amel | Alendronate Mylan | Alendronate Towa | Alendronic acid towa | Bonalon | Fosamac</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bongard | Landronate | Maxlen | Menofos | Osteofos | Reventa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aidbon | Airend | Aland | Alangdelon | Albone | Aldren | Aledlon | Aledron | Alen d | Alend | Alenda | Alendrex | Alendro | Alendronate | Alendros | Alene | Alenfos | Alenmax | Alenstar | Alent | Alentop | Aleron | Alfomax | Allenmax | Allentop | Alobon | Alonate | Alont | Alront | Arangdron | Arenbon | Arond | Ausomax | Binosto | Bisbon | Bolend | Bonadron | Bonaid | Bonalen | Bonamax | Bonmax | Bonomax | Bonpill | Calmax | Daewoong alendronate | Foalen | Folend | Forend | Forenmax | Fosaalen | Fosaalon | Fosalen | Fosalend | Fosalong | Fosalonin | Fosamax | Fosanet | Fosaqueen | Fosaron | Ginodron | Gynodron | Kingdron | Lite alendron | Malend | Marend | Marvil | Masibone | Momax | Newsendro | Os | Parend | Polenmax | Tevanate | Tibone | Tibone weekly</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Alendronate sandoz | Fosamax | Fozanate | Lendomax | Osteo</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alendomax | Bonmax | Drolate | Fosamax | Osteomed | Osteve</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico semanal Kern Pharma | Alendon | Alendronic acid accord | Alendronic acid actiopharma | Alenotop | Fosamax | Lindron | Ralenost | Sedron | Tevanate</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Alendron | Alendronate EG | Alendronate sandoz | Alendronsaeure Ratio | Beenos | Fosamax | Ostacid</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fosamax | Ostemax | Ralenost</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Acide Alendronique Gt | Acide Alendronique Normon | Adronat | Anor | Fosamax | Inros</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Alendronato | Alendronato Ultra | Alsix | Apodrolen | Bifosmac | Blindafe | Cistros | Denofel | Dronadil | Drovitan | Fosalacin | Fosamax | Kalosten | Landrolen | Lenadrin | Oxivag | Sinfract | Synostep</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alendronate | Alendronate sandoz | Alendronic acid | Apo alendronate | Apodrolen | Binosto | Fosamax | Ralenost</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Alendroninezr | Alendroninezuur A | Alendroninezuur Accord | Alendroninezuur actavis | Alendroninezuur cf | Alendroninezuur KR | Alendroninezuur mylan | Alendroninezuur PCH | Alendroninezuur ratiopharm | Alendroninezuur sandoz | Bonasol | Dronal | Fosamax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Alendronat | Alendronat Arrow | Alendronat Bluefish | Alendronat Teva | Alendronat Unimedic | Alendronic acid accord | Alendronic acid teva | Binosto | Fosamax</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Fosamax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico | Alendra 7 | Alendron | Alendronato | Alendronato sodico | Alendroporosis | Alenost | Alostal | Arendal | Bonaliv | Durost | Endronal | Eucalen | Fijacalcin | Fixopan | Fosamax | Fosavit | Fosmin | Fosval | Holadren | Lafedam | Leandronato | Marvil | Osteosan | Poris | Zondral</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Aldren | Alendra | Alendroxl | Alovell | Binosto | Bondros | Forosa | Fosamax | Osteocor | Osteomax | Reventa | Tevanate</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Alendrate | Alendroflex | Alendrogen | Alendrowin | Alidium | Andonat | Bonafide | Bonate | Bonfit | Bongard | Bonpart | Bostrong | Botic | Denfos | Drate | Dyronate | Firmofos | Fosamax | Fosnate | Lendra | No prosis | Orthonate | Ossel | Ostamed | Osteopor | Reventa</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Alenato | Alendran | Alendrolek | Alendronat aurobindo | Alendronat Bluefish | Alendronate Arrow | Alendronic acid genoptim | Alenotop | Fosamax | Lindron | Osalen | Ostemax comfort | Ostenil | Ostodronic | Ostolek | Rekostin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Binosto | Fosamax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico | Acido alendronico almus | Acido alendronico arrowblue | Acido alendronico aurobindo | Acido Alendronico Azevedos | Acido alendronico bifosal | Acido Alendronico Farmoz | Acido alendronico frosst | Acido alendronico generis | Acido Alendronico GP | Acido alendronico j. neves | Acido alendronico jaba | Acido alendronico Mepha | Acido alendronico ratiopharm | Acido alendronico sandoz | Adronat | Alegonat | Aleostito | Binosto | Bonasol | Fosamax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Alend | Alendronato dallas | Alendronato genfar | Arendal | Atralon | Discal | Fosval | Holadren | Osteol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Alendro | Alendronate Sandoz | Binosto | Fosamax Once Weekly | Osteo-Acino | Osteve</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acid alendronic accord | Acid alendronic aurobindo | Alendronat sandoz | Fosamax | Ranos | Tevanat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Alendrokern | Alendronate | Binosto | Forosa | Fosamax | Lindron | Ostalon | Osterepar | Strongos | Tevanate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Alendocan | Alendro | Alendronate sandoz | Apo alendronate | Bonamax | Drolate | Fosamax | Fozanate | Lendomax | Osteo | Osteodens | Osteomax | Osteve | Pms-alendronate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Alenat | Alendronat Accord | Alendronat aristo veckotablett | Alendronat Arrow | Alendronat aurobindo veckotablett | Alendronat Bluefish | Alendronat ebb veckotablett | Alendronat mds veckotablett | Alendronat mylan | Alendronat Orifarm | Alendronat paranova veckotablett | Alendronat Ranbaxy | Alendronat sandoz | Alendronat Stada | Alendronat Teva | Alendronat Unimedic | Binosto | Fosamax</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alendronate sandoz | Apo alendronate | Binosto | Fosamax | Lendomax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Alenax | Alendor | Alendronat Arrow | Fosamax | Lindron | Tevanate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Alendromax | Alendronat | Fosamax | Gendron | Siranin | Tevalen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Aldren | Alendronate sandoz | Bonmax | Fosamax | Maxlen | Pleofix | Ralenost</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Fosalen | Fosamax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alemaks | Andante | As Aldeks | Bonacton | Bonemax | Fosamax | Osalen | Osteomax | Vegabon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Alendronate sandoz | Apo alendronate | Binosto | Covaxin | Fosamax</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Alendon 10 | Alendon 70 | Alendra | Alendronat sandoz | Alendronat stoma | Fosamax | Londromax | Ostemax | Osteo | Osteofos | Ralenost</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Aldren | Alendronate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Alendral | Alendronato | Bones | Gerical | Marvil | Osteonato | Osteopor</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acido alendronico | Aldronac | Alendron | Alendronato | Alendronato sodico | Aliot | Defixal | Denfos | Fixopan | Fosamax | Genalmen | Osteodur | Osteomax | Porosal</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Messi | Sagafosa | Vonland</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Alendronate | Aldren | Alendronate | Alendronate unicorn | Boniran | Densate | Fosamax | Ostena | Osteobon | Osteonate | Ran alendronate | Solibon</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Alendro | Relenost | Zophost</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-26350171">
<a name="26350171"></a>Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research [published correction appears in <i>J Bone Miner Res</i>. 2016;31(10):1910]. <i>J Bone Miner Res</i>. 2016;31(1):16-35. doi: 10.1002/jbmr.2708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/26350171/pubmed" id="26350171" target="_blank">26350171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21736407">
<a name="21736407"></a>Aibar Arregui MA, de Escalante Yangüela B, Muñoz Villalengua M, Garcés Horna V. Esophageal stenosis caused by alendronate. <i>Rev Esp Enferm Dig</i>. 2011;103(6):338-339. doi: 10.4321/s1130-01082011000600015.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21736407/pubmed" id="21736407" target="_blank">21736407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310788">
<a name="18310788"></a>Akcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. <i>Indian Pediatr</i>. 2008;45(2):105-109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/18310788/pubmed" id="18310788" target="_blank">18310788</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Alendronate sodium oral solution [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc; September 2020.</div>
</li>
<li>
<div class="reference">
                  Alendronate sodium tablet [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; July 2023.</div>
</li>
<li>
<div class="reference">
                  Alendronate sodium tablet [prescribing information]. Warren, NJ: Cipla USA, Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28169118">
<a name="28169118"></a>Alibhai SMH, Zukotynski K, Walker-Dilks C, et al; Cancer Care Ontario Genitourinary Cancer Disease Site Group. Bone health and bone-targeted therapies for prostate cancer: a programme in evidence-based care - Cancer Care Ontario clinical practice guideline. <i>Clin Oncol (R Coll Radiol)</i>. 2017;29(6):348-355. doi:10.1016/j.clon.2017.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/28169118/pubmed" id="28169118" target="_blank">28169118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19371816">
<a name="19371816"></a>Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. <i>J Oral Maxillofac Surg</i>. 2009;67(5 Suppl):61-70. doi:10.1016/j.joms.2009.01.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19371816/pubmed" id="19371816" target="_blank">19371816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16873332">
<a name="16873332"></a>American Dental Association Council on Scientific Affairs, “Dental Management of Patients Receiving Oral Bisphosphonate Therapy,” <i>JADA</i>, 2006, 137(8):1144-50. Available at http://jada.ada.org/article/S0002-8177(14)64960-6/pdf
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16873332/pubmed" id="16873332" target="_blank">16873332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17912140">
<a name="17912140"></a>Apkon S, Coll J. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. <i>Am J Phys Med Rehabil</i>. 2008;87(2):139-143.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17912140/pubmed" id="17912140" target="_blank">17912140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Alendronate.1">
<a name="Alendronate.1"></a>APO-Alendronate (alendronate) [prescribing information]. Toronto, Ontario, Canada: Apotex Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Safety.1">
<a name="Safety.1"></a>Author Unknown. Safety update: bone-building drugs: risks explained. <i>Consum Rep Health.</i> 2006. 18(5):3.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bailie.1">
<a name="Bailie.1"></a>Bailie GR, Mason NA. <i>Bailie and Mason’s 2020 Dialysis of Drugs</i>. Renal Pharmacy Consultants LLC. 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20534366">
<a name="20534366"></a>Bhalla AK. Management of osteoporosis in a pre-menopausal woman. <i>Best Pract Res Clin Rheumatol</i>. 2010;24(3):313-327. doi:10.1016/j.berh.2010.01.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20534366/pubmed" id="20534366" target="_blank">20534366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11014345">
<a name="11014345"></a>Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. <i>Arthritis Rheum</i>. 2000;43(9):1960-1966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/11014345/pubmed" id="11014345" target="_blank">11014345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24429202">
<a name="24429202"></a>Bianchi ML, Colombo C, Assael BM, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. <i>Lancet Respir Med</i>. 2013;1(5):377-385. doi:10.1016/S2213-2600(13)70064-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/24429202/pubmed" id="24429202" target="_blank">24429202</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Binosto (alendronate) [prescribing information]. Boston, MA: Radius Health, Inc; October 2023.</div>
</li>
<li>
<div class="reference">
                  Binosto (alendronate) [prescribing information]. Morristown, NJ: Ascend Therapeutics; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30169557">
<a name="30169557"></a>Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management.<i> Endocr Rev</i>. 2019;40(2):333-368. doi: 10.1210/er.2018-00001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/30169557/pubmed" id="30169557" target="_blank">30169557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32813950">
<a name="32813950"></a>Black DM, Geiger EJ, Eastell R, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. <i>N Engl J Med</i>. 2020;383(8):743-753. doi:10.1056/NEJMoa1916525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/32813950/pubmed" id="32813950" target="_blank">32813950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17097529">
<a name="17097529"></a>Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. <i>J Clin Densitom</i>. 2006;9(4):431-437.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17097529/pubmed" id="17097529" target="_blank">17097529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28585373">
<a name="28585373"></a>Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in <i>Arthritis Rheum. </i>2017;69(11):2246]. <i>Arthritis Rheumatol</i>. 2017;69(8):1521-1537.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/28585373/pubmed" id="28585373" target="_blank">28585373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32427503">
<a name="32427503"></a>Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. <i>Endocr Pract</i>. 2020;26(suppl 1):s1-s46. doi:10.4158/GL-2020-0524SUPPL<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/32427503/pubmed" id="32427503" target="_blank">32427503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18167381">
<a name="18167381"></a>Cartsos VM, Zhu S, and Zavras AI, “Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A Medical Claims Study of 714,217 People,” <i>J Am Dent Assoc</i>, 2008, 139(1):23-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/18167381/pubmed" id="18167381" target="_blank">18167381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Charles.1">
<a name="Charles.1"></a>Charles JF. Treatment of Paget disease of bone. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 17, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8298198">
<a name="8298198"></a>Chesnut CH 3rd, Harris ST. Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women. <i>Osteoporos Int</i>. 1993;3 suppl 3:S17-19. doi: 10.1007/BF01623003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/8298198/pubmed" id="8298198" target="_blank">8298198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24758181">
<a name="24758181"></a>Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. <i>J Clin Endocrinol Metab</i>. 2014;99(8):2729-2735. doi: 10.1210/jc.2013-4119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/24758181/pubmed" id="24758181" target="_blank">24758181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19212145">
<a name="19212145"></a>Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. <i>Oncology.</i> 2009;76(3):209-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19212145/pubmed" id="19212145" target="_blank">19212145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12180745">
<a name="12180745"></a>Cimaz R, Gattorno M, Sormani MP, et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. <i>J Rheumatol</i>. 2002;29(8):1786-1792.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/12180745/pubmed" id="12180745" target="_blank">12180745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16914703">
<a name="16914703"></a>de Nijs RN, Jacobs JW, Lems WF, et al; STOP Investigators. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.<i> N Engl J Med.</i> 2006;355(7):675-684. doi: 10.1056/NEJMoa053569.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16914703/pubmed" id="16914703" target="_blank">16914703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8793925">
<a name="8793925"></a>de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. <i>N Engl J Med</i>. 1996;335(14):1016-1021. doi:10.1056/NEJM199610033351403<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/8793925/pubmed" id="8793925" target="_blank">8793925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19175968">
<a name="19175968"></a>Djokanovic N, Klieger-Grossmann C, and Koren G, "Does Treatment With Bisphosphonates Endanger the Human Pregnancy?" <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19175968/pubmed" id="19175968" target="_blank">19175968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16000365">
<a name="16000365"></a>Durie BG, Katz M, and Crowley J, "Osteonecrosis of the Jaw and Bisphosphonates," <i>N Engl J Med</i>, 2005, 353(1):99-102.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16000365/pubmed" id="16000365" target="_blank">16000365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19047674">
<a name="19047674"></a>Edwards BJ, Hellstein JW, Jacobsen PL, et al, “Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,” <i> J Am Dent Assoc</i>, 2008, 139(12):1674-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19047674/pubmed" id="19047674" target="_blank">19047674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2018">
<a name="FDA.2018"></a>FDA Drug Safety Communication 2018. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Published October 13, 2010. Accessed November 23, 2020. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-safety-update-osteoporosis-drugs-bisphosphonates-and-atypical</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20508948">
<a name="20508948"></a>Filleul O, Crompot E, and Saussez S, "Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases," <i>J Cancer Res Clin Oncol</i>, 2010, 136(8):1117-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20508948/pubmed" id="20508948" target="_blank">20508948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Finkelstein.1">
<a name="Finkelstein.1"></a>Finkelstein JS, Yu EW. Treatment of osteoporosis in men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 12, 2021.</div>
</li>
<li>
<div class="reference">
                  Fosamax (alendronate) [prescribing information]. Jersey City, NJ: Organon LLC; June 2021.</div>
</li>
<li>
<div class="reference">
                  Fosamax (alendronate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; August 2023.</div>
</li>
<li>
<div class="reference">
                  Fosamax (alendronate) [product monograph]. Kirkland, Quebec, Canada: Organon Canada Inc; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17614762">
<a name="17614762"></a>Galluzzo S, Santini D, Vincenzi B, et al. Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. <i>Expert Opin Ther Targets</i>. 2007;11(7):941-954. doi: 10.1517/14728222.11.7.941.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17614762/pubmed" id="17614762" target="_blank">17614762</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27150561">
<a name="27150561"></a>Gerin M, Jambon G, Fouque-Aubert A, et al. Neonatal transient hypophosphatemic hypercalciuric rickets in dizygous twins: A role for maternal alendronate therapy before pregnancy or antireflux medications? <i>Arch Pediatr</i>. 2016;23(9):957-962.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/27150561/pubmed" id="27150561" target="_blank">27150561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7554702">
<a name="7554702"></a>Gertz BJ, Holland SD, Kline WF, et al. Studies of the oral bioavailability of alendronate. <i>Clin Pharmacol Ther.</i> 1995;58(3):288-298. doi: 10.1016/0009-9236(95)90245-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/7554702/pubmed" id="7554702" target="_blank">7554702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25404594">
<a name="25404594"></a>Green SB, Pappas AL. Effects of maternal bisphosphonate use on fetal and neonatal outcomes. <i>Am J Health Syst Pharm</i>. 2014;71(23):2029-2036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25404594/pubmed" id="25404594" target="_blank">25404594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17371886">
<a name="17371886"></a>Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. <i>Ann Intern Med</i>. 2007;146(6):416-424.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17371886/pubmed" id="17371886" target="_blank">17371886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18802155">
<a name="18802155"></a>Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. <i>J Clin Oncol</i>. 2008;26(27):4426-4434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/18802155/pubmed" id="18802155" target="_blank">18802155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35378630">
<a name="35378630"></a>Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. <i>Arch Osteoporos.</i> 2022;17(1):58. doi:10.1007/s11657-022-01061-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/35378630/pubmed" id="35378630" target="_blank">35378630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28602783">
<a name="28602783"></a>Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. <i>J Am Pharm Assoc</i> (2003). 2017;57(4):503-509. doi: 10.1016/j.japh.2017.05.003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/28602783/pubmed" id="28602783" target="_blank">28602783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16454811">
<a name="16454811"></a>Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. <i>J Oral Pathol Med</i>. 2006;35(3):155-160. doi: 10.1111/j.1600-0714.2006.00391.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16454811/pubmed" id="16454811" target="_blank">16454811</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22041409">
<a name="22041409"></a>Hellstein JW, Adler RA, Edwards B, et al, "Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Executive Summary of Recommendations From the American Dental Association Council on Scientific Affairs," <i>J Am Dent Assoc</i>, 2011, 142(11):1243-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22041409/pubmed" id="22041409" target="_blank">22041409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hellstein.1">
<a name="Hellstein.1"></a>Hellstein JW, Adler RA, Edwards B, et al, "Managing the Care of Patients Receiving Antiresorptive Therapy for Prevention and Treatment of Osteoporosis: Recommendations From the American Dental Association Council on Scientific Affairs," 2011, Available at http://www.ada.org/~/media/ADA/Member%20Center/FIles/topics_ARONJ_report.ashx. Accessed February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23835890">
<a name="23835890"></a>Houston C, Mathews K, Shibli-Rahhal A. Bone density and alendronate effects in Duchenne muscular dystrophy patients. <i>Muscle Nerve</i>. 2014;49(4):506-511.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/23835890/pubmed" id="23835890" target="_blank">23835890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573608">
<a name="31573608"></a>Jacobson DL, Lindsey JC, Gordon C, et al. Alendronate improves bone mineral density in children and adolescents perinatally infected with human immunodeficiency virus with low bone mineral density for age. <i>Clin Infect Dis</i>. 2020;71(5):1281-1288. doi:10.1093/cid/ciz957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/31573608/pubmed" id="31573608" target="_blank">31573608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10878202">
<a name="10878202"></a>Kashyap AS, Kashyap S. Hypoparathyroidism unmasked by alendronate. <i>Postgrad Med J</i>. 2000;76(897):417-418. doi: 10.1136/pmj.76.897.417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/10878202/pubmed" id="10878202" target="_blank">10878202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25710950">
<a name="25710950"></a>Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. <i>J Dent Res</i>. 2015;94(4):534-539. doi:10.1177/0022034515572021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25710950/pubmed" id="25710950" target="_blank">25710950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25414052">
<a name="25414052"></a>Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J Bone Miner Res.</i> 2015; 30(1):3-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25414052/pubmed" id="25414052" target="_blank">25414052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20674418">
<a name="20674418"></a>Kharazmi M, Sjöqvist K, Rizk M, Warfvinge G. Oral ulcer associated with alendronate: a case report. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2010;110(6):e11-13. doi: 10.1016/j.tripleo.2010.04.035.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20674418/pubmed" id="20674418" target="_blank">20674418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21816532">
<a name="21816532"></a>Kharazmi M, Sjöqvist K, Warfvinge G. Oral ulcers, a little known adverse effect of alendronate: review of the literature. <i>J Oral Maxillofac Surg</i>. 2012;70(4):830-836. doi: 10.1016/j.joms.2011.03.046.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21816532/pubmed" id="21816532" target="_blank">21816532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17663640">
<a name="17663640"></a>Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.<i> J Bone Miner Res</i>. 2007;22(10):1479-1491. doi: 10.1359/jbmr.0707onj.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17663640/pubmed" id="17663640" target="_blank">17663640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23040208">
<a name="23040208"></a>Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL; Canadian Urology Research Consortium. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. <i>Eur Urol</i>. 2013;63(5):927-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/23040208/pubmed" id="23040208" target="_blank">23040208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11200854">
<a name="11200854"></a>Kontoleon P, Ilias I, Stavropoulos PG, Papapetrou PD. Urticaria after administration of alendronate. <i>Acta Derm Venereol</i>. 2000;80(5):398<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/11200854/pubmed" id="11200854" target="_blank">11200854</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17805035">
<a name="17805035"></a>Lethaby C, Wiernikowski J, Sala A, Naronha M, Webber C, Barr RD. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. <i>J Pediatr Hematol Oncol</i>. 2007;29(9):613-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17805035/pubmed" id="17805035" target="_blank">17805035</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16108245">
<a name="16108245"></a>Leung S, Ashar BH, Miller RG. Bisphosphonate-associated scleritis: a case report and review. <i>South Med J</i>. 2005;98(7):733-735. doi:10.1097/01.SMJ.0000152753.80490.9F<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16108245/pubmed" id="16108245" target="_blank">16108245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19059370">
<a name="19059370"></a>Levy S, Fayez I, Taguchi N, et al, "Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates," <i>Bone</i>, 2009, 44(3):428-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19059370/pubmed" id="19059370" target="_blank">19059370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lewiecki.1">
<a name="Lewiecki.1"></a>Lewiecki EM. Prevention of osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21504254">
<a name="21504254"></a>Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. <i>Drugs</i>. 2011;71(6):791-814. doi: 10.2165/11585470-000000000-00000.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21504254/pubmed" id="21504254" target="_blank">21504254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24515577">
<a name="24515577"></a>Lin TC, Yang CY, Kao Yang YH, Lin SJ. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population. <i>Osteoporos Int</i>. 2014;25(5):1503-1511. doi: 10.1007/s00198-014-2624-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/24515577/pubmed" id="24515577" target="_blank">24515577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19772941">
<a name="19772941"></a>Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. <i>J Oral Maxillofac Surg.</i> 2010;68(2):243-253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19772941/pubmed" id="19772941" target="_blank">19772941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31497503">
<a name="31497503"></a>Lockwood M, Banderudrappagari R, Suva LJ, Makhoul I. Atypical femoral fractures from bisphosphonate in cancer patients - Review. <i>J Bone Oncol</i>. 2019;18:100259. doi: 10.1016/j.jbo.2019.100259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/31497503/pubmed" id="31497503" target="_blank">31497503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16524863">
<a name="16524863"></a>Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. <i>Endocr Pract</i>. 2006;12(1):48-53. doi: 10.4158/EP.12.1.48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16524863/pubmed" id="16524863" target="_blank">16524863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36729669">
<a name="36729669"></a>MacDonald P, Cranston A, Virdee M, Farncombe T, Athale U, Barr RD. Safety and efficacy of alendronate to treat osteopenia in children during therapy for acute lymphoblastic leukemia: a retrospective cohort study of sequential outcomes. <i>J Pediatr Hematol Oncol</i>. 2023;45(4):200-206. doi:10.1097/MPH.0000000000002606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/36729669/pubmed" id="36729669" target="_blank">36729669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31539355">
<a name="31539355"></a>Machairiotis N, Ntali G, Kouroutou P, Michala L. Clinical evidence of the effect of bisphosphonates on pregnancy and the infant. <i>Horm Mol Biol Clin Investig</i>. 2019;40(2). doi:10.1515/hmbci-2019-0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/31539355/pubmed" id="31539355" target="_blank">31539355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12446386">
<a name="12446386"></a>Malik AR, Campbell SH, Toma NM. Bilateral acute anterior uveitis after alendronate. <i>Br J Ophthalmol</i>. 2002;86(12):1443. doi:10.1136/bjo.86.12.1443<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/12446386/pubmed" id="12446386" target="_blank">12446386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12966493">
<a name="12966493"></a>Marx RE. Pamidronate (<i>Aredia</i>) and zoledronate (<i>Zometa</i>) induced avascular necrosis of the jaws: a growing epidemic. <i>J Oral Maxillofac Surg</i>. 2003;61(9):1115-1117. doi: 10.1016/s0278-2391(03)00720-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/12966493/pubmed" id="12966493" target="_blank">12966493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243172">
<a name="16243172"></a>Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. <i>J Oral Maxillofac Surg</i>. 2005;63(11):1567-1575. doi: 10.1016/j.joms.2005.07.010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16243172/pubmed" id="16243172" target="_blank">16243172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17307586">
<a name="17307586"></a>Mavrokokki T, Cheng A, Stein B, et al, “Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,” <i>J Oral Maxillofac Surg</i>, 2007, 65(3):415-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17307586/pubmed" id="17307586" target="_blank">17307586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25866298">
<a name="25866298"></a>Modi A, Siris ES, Steve Fan CP, Sajjan S. Gastrointestinal events among patients initiating osteoporosis therapy: A retrospective administrative claims database analysis.<i> Clin Ther</i>. 2015;37(6):1228-1234. doi: 10.1016/j.clinthera.2015.03.018.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25866298/pubmed" id="25866298" target="_blank">25866298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27112533">
<a name="27112533"></a>Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J. Relationship between gastrointestinal events and compliance with osteoporosis therapy: an administrative claims analysis of the US managed care population. <i>Clin Ther</i>. 2016;38(5):1074-1080. doi:10.1016/j.clinthera.2016.03.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/27112533/pubmed" id="27112533" target="_blank">27112533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22778283">
<a name="22778283"></a>Munigoti S, Frazer R, Rees A, Blackshaw G, Thomas G, Roberts A. A rare complication with a single dose of alendronate. <i>BMJ Case Rep</i>. 2010;2010:bcr0220102738. doi: 10.1136/bcr.02.2010.2738.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22778283/pubmed" id="22778283" target="_blank">22778283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21962451">
<a name="21962451"></a>Nakhla M, Denker AE, Connor JD, et al. Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. <i>Clin Ther. </i>2011;33(10):1516-1523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21962451/pubmed" id="21962451" target="_blank">21962451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30393090">
<a name="30393090"></a>Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surg Oral Med Oral Pathol Oral Radiol</i>. 2019;127(2):117-135. doi: 10.1016/j.oooo.2018.09.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/30393090/pubmed" id="30393090" target="_blank">30393090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34448749">
<a name="34448749"></a>North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. <i>Menopause</i>. 2021;28(9):973-997. doi:10.1097/GME.0000000000001831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/34448749/pubmed" id="34448749" target="_blank">34448749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16996245">
<a name="16996245"></a>Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. <i>Reprod Toxicol</i>. 2006;22(4):578-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16996245/pubmed" id="16996245" target="_blank">16996245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28863000">
<a name="28863000"></a>Palomo T, Vilaça T, Lazaretti-Castro M. Osteogenesis imperfecta: diagnosis and treatment. <i>Curr Opin Endocrinol Diabetes Obes</i>. 2017;24(6):381-388. doi:10.1097/MED.0000000000000367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/28863000/pubmed" id="28863000" target="_blank">28863000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343577">
<a name="21343577"></a>Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. <i>JAMA</i>. 2011;305(8):783-789. doi: 10.1001/jama.2011.190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21343577/pubmed" id="21343577" target="_blank">21343577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21343270">
<a name="21343270"></a>Paul AK, Seetharaman M. Esophageal stricture associated with alendronate use. <i>CMAJ</i>. 2011;183(7):E429. doi: 10.1503/cmaj.100415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21343270/pubmed" id="21343270" target="_blank">21343270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16678644">
<a name="16678644"></a>Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. <i>Clin Ther</i>. 2006;28(2):236-242. doi: 10.1016/j.clinthera.2006.01.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16678644/pubmed" id="16678644" target="_blank">16678644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32453819">
<a name="32453819"></a>Pepe J, Body JJ, Hadji P, et al. Osteoporosis in premenopausal women: a clinical narrative review by the ECTS and the IOF. <i>J Clin Endocrinol Metab</i>. 2020;105(8):dgaa306. doi:10.1210/clinem/dgaa306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/32453819/pubmed" id="32453819" target="_blank">32453819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22885424">
<a name="22885424"></a>Pereira RM, Carvalho JF, Paula AP, et al, "Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis," <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22885424/pubmed" id="22885424" target="_blank">22885424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15832149">
<a name="15832149"></a>Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. <i>J Pediatr Orthop</i>. 2005;25(3):332-335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/15832149/pubmed" id="15832149" target="_blank">15832149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30803025">
<a name="30803025"></a>Ralston SH, Corral-Gudino L, Cooper C, et al. Diagnosis and management of Paget's disease of bone in adults: a clinical guideline. <i>J Bone Miner Res</i>. 2019;34(4):579-604. doi: 10.1002/jbmr.3657.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/30803025/pubmed" id="30803025" target="_blank">30803025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15110498">
<a name="15110498"></a>Rauch F, Glorieux FH. Osteogenesis imperfecta. <i>Lancet</i>. 2004;363(9418):1377-1385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/15110498/pubmed" id="15110498" target="_blank">15110498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16291701">
<a name="16291701"></a>Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. <i>J Clin Endocrinol Metab</i>. 2006;91(2):511-516.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16291701/pubmed" id="16291701" target="_blank">16291701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.2">
<a name="Rosen.2"></a>Rosen HN. The use of bisphosphonates in postmenopausal women with osteoporosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 22, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rosen.1">
<a name="Rosen.1"></a>Rosen HN, Drezner MK. Overview of the management of osteoporosis in postmenopausal women. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 4, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693577">
<a name="31693577"></a>Rossi V, Lee B, Marom R. Osteogenesis imperfecta: advancements in genetics and treatment. <i>Curr Opin Pediatr</i>. 2019;31(6):708-715. doi:10.1097/MOP.0000000000000813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/31693577/pubmed" id="31693577" target="_blank">31693577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20871729">
<a name="20871729"></a>Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. <i>J Clin Oncol.</i> 2006. 2(1):7-14. doi: 10.1200/JOP.2006.2.1.7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20871729/pubmed" id="20871729" target="_blank">20871729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9682041">
<a name="9682041"></a>Saag KG, Emkey R, Schnitzer TJ, et al, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. <i>N Engl J Med</i>. 1998;339(5):292-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/9682041/pubmed" id="9682041" target="_blank">9682041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31990618">
<a name="31990618"></a>Saylor PJ, Rumble RB, Tagawa S, et al. Bone health and bone-targeted therapies for prostate cancer: ASCO endorsement of a Cancer Care Ontario guideline. <i>J Clin Oncol</i>. 2020;38(15):1736-1743. doi:10.1200/JCO.19.03148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/31990618/pubmed" id="31990618" target="_blank">31990618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10068397">
<a name="10068397"></a>Schussheim DH, Jacobs TP, Silverberg SJ. Hypocalcemia associated with alendronate. <i>Ann Intern Med</i>. 1999;130(4 pt 1):329. doi: 10.7326/0003-4819-130-4-199902160-00008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/10068397/pubmed" id="10068397" target="_blank">10068397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16294137">
<a name="16294137"></a>Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. <i>J Pediatr Orthop</i>. 2005;25(6):786-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16294137/pubmed" id="16294137" target="_blank">16294137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20842676">
<a name="20842676"></a>Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research [published correction appears in J Bone Miner Res. 2011 Aug;26(8):1987]. <i>J Bone Miner Res</i>. 2010;25(11):2267-2294. doi:10.1002/jbmr.253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20842676/pubmed" id="20842676" target="_blank">20842676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23712442">
<a name="23712442"></a>Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>J Bone Miner Res</i>. 2014;29(1):1-23. doi: 10.1002/jbmr.1998.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/23712442/pubmed" id="23712442" target="_blank">23712442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532726">
<a name="31532726"></a>Shapiro CL, Van Poznak C, Lacchetti C, et al. Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline. <i>J Clin Oncol</i>. 2019;37(31):2916-2946. doi:10.1200/JCO.19.01696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/31532726/pubmed" id="31532726" target="_blank">31532726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29504223">
<a name="29504223"></a>Simm PJ, Biggin A, Zacharin MR, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. <i>J Paediatr Child Health</i>. 2018;54(3):223-233. doi:10.1111/jpc.13768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/29504223/pubmed" id="29504223" target="_blank">29504223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25406796">
<a name="25406796"></a>Singer FR 3rd, Bone HG, Hosking DJ, et al; Endocrine Society. Paget's disease of bone: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25406796/pubmed" id="25406796" target="_blank">25406796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Smith.1">
<a name="Smith.1"></a>Smith MR. Side effects of androgen deprivation therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 5, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30171300">
<a name="30171300"></a>Sokal A, Elefant E, Leturcq T, Beghin D, Mariette X, Seror R. Pregnancy and newborn outcomes after exposure to bisphosphonates: a case-control study. <i>Osteoporos Int</i>. 2019;30(1):221-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/30171300/pubmed" id="30171300" target="_blank">30171300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22281884">
<a name="22281884"></a>Stathopoulos IP, Liakou CG, Katsalira A, et al, "The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation," <i>Hormones (Athens)'</i>, 2011, 10(4):280-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22281884/pubmed" id="22281884" target="_blank">22281884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19487264">
<a name="19487264"></a>Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. <i>J Rheumatol.</i> 2009;36(8):1705-1714. doi: 10.3899/jrheum.081207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19487264/pubmed" id="19487264" target="_blank">19487264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22105813">
<a name="22105813"></a>Tee SI, Yosipovitch G, Chan YC, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study. <i>Arch Dermatol</i>. 2012;148(3):307-314. doi: 10.1001/archdermatol.2011.354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22105813/pubmed" id="22105813" target="_blank">22105813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12947959">
<a name="12947959"></a>Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. <i>Am J Med</i>. 2003;115(3):209-216. doi: 10.1016/s0002-9343(03)00362-0.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/12947959/pubmed" id="12947959" target="_blank">12947959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20347511">
<a name="20347511"></a>Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. <i>Am J Kidney Dis</i>. 2010;56(1):57-68. doi:10.1053/j.ajkd.2009.12.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20347511/pubmed" id="20347511" target="_blank">20347511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16759038">
<a name="16759038"></a>Unal E, Abaci A, Bober E, Büyükgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. <i>J Pediatr Endocrinol Metab</i>. 2006;19(4):523-528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16759038/pubmed" id="16759038" target="_blank">16759038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21764202">
<a name="21764202"></a>Vestergaard P, Schwartz K, Rejnmark L, Mosekilde L, Pinholt EM. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study. <i>J Oral Maxillofac Surg</i>. 2012;70(4):821-829. doi: 10.1016/j.joms.2011.02.093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21764202/pubmed" id="21764202" target="_blank">21764202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21106710">
<a name="21106710"></a>Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfect: a randomized placebo-controlled study. <i>J Clin Endocrinol Metab</i>. 2011;96(2):355-364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21106710/pubmed" id="21106710" target="_blank">21106710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22675062">
<a name="22675062"></a>Watts NB, Adler RA, Bilezikian JP, et al; Endocrine Society. Osteoporosis in men: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2012;97(6):1802-1822. doi: 10.1210/jc.2011-3045.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22675062/pubmed" id="22675062" target="_blank">22675062</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20173017">
<a name="20173017"></a>Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. <i>J Clin Endocrinol Metab</i>. 2010;95(4):1555-1565. doi: 10.1210/jc.2009-1947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20173017/pubmed" id="20173017" target="_blank">20173017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30626809">
<a name="30626809"></a>Yamamoto K, Kishino M, Nakamura S, Tokushige K. Symptoms and upper gastrointestinal mucosal injury associated with bisphosphonate therapy. <i>Intern Med</i>. 2019;58(8):1049-1056. doi:10.2169/internalmedicine.1271-18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/30626809/pubmed" id="30626809" target="_blank">30626809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19004038">
<a name="19004038"></a>Yeap SS, Fauzi AR, Kong NC, et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. <i>J Rheumatol.</i> 2008;35(12):2344-2347. doi: 10.3899/jrheum.080634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19004038/pubmed" id="19004038" target="_blank">19004038</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 114896 Version 287.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
